首页> 外文期刊>Experimental and clinical transplantation >Successful ABO-Incompatible Liver Transplantation with Pre- and Postoperative Plasmapheresis, Triple Immunosuppression, and Splenectomy for Fulminant Hepatic Failure
【24h】

Successful ABO-Incompatible Liver Transplantation with Pre- and Postoperative Plasmapheresis, Triple Immunosuppression, and Splenectomy for Fulminant Hepatic Failure

机译:术前和术后血浆置换,三重免疫抑制和脾切除术成功进行ABO不相容性肝移植治疗重型肝衰竭

获取原文
           

摘要

Fulminant hepatic failure continues to be a challenge to hepatologists and surgeons. Because of the rapid deterioration in the clinical condition of patients with fulminant hepatic failure and the scarcity of available grafts, an ABO-incompatible liver donor may be the only choice for a patient with life-threatening hepatic insufficiency. Here, we report a patient with fulminant hepatic failure who received an ABO-incompatible liver transplantation who was treated with pre- and posttransplantation double-volume total plasma exchange, splenectomy, and triple immunosuppression (tacrolimus, mycophenolate mofetil, and prednisone) in July 2003. At 26 months’ follow-up, the patient’s postoperative course has been uneventful. Using protocols aimed at removing existing isohemagglutinins and reducing further antibody production, ABO-incompatible liver transplantation may be performed as a life-saving procedure in patients with fulminant hepatic failure.
机译:剧烈的肝功能衰竭仍然是肝病学家和外科医生的挑战。由于暴发性肝衰竭患者的临床状况迅速恶化,并且缺乏可用的移植物,因此,与ABO不相容的肝供体可能是威胁生命的肝功能不全患者的唯一选择。在这里,我们报道了2003年7月接受过ABO不相容肝移植的暴发性肝衰竭患者,该患者在移植前后均进行了双体积总血浆置换,脾切除术和三重免疫抑制(他克莫司,霉酚酸酯和泼尼松)治疗在26个月的随访中,患者的术后过程一直保持平稳。使用旨在去除现有异血凝素并减少进一步抗体产生的方案,对于暴发性肝衰竭患者,可以进行ABO不相容的肝移植作为挽救生命的程序。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号